News

JAMA study reveals use of dexamethasone and others in non-hospitalized patients with mild to moderate illness.

Investigators identify 11 crucial “protection-defining genes” that prevent a severe disease response to COVID-19 infection.

The organization has its upcoming antimicrobial stewardship meeting in less than two weeks, and offers professional education and training in infectious diseases with a special emphasis on antimicrobial stewardship.

The federal agency revised the vaccine’s Emergency Use Authorization after an analysis of the risk for thrombosis with thrombocytopenia syndrome (TTS).

The number of Americans who opt for an additional booster dose of a COVID-19 vaccine may be limited.

Researchers looked at the serial use of homologous and heterologous boosters in open-label clinical trials across 10 US sites.

Though a valid scientific approach, it may assume benefits incorrectly, researchers warn.

HIV reservoirs can remain dormant, reigniting infection at an opportune moment. New strategies seek to reignite these viral reservoirs so they can be identified and destroyed by the immune system.

Antibiotic-resistant strains of the dangerous superbug C difficile have been identified in pigs and humans, suggesting zoonotic transmission is possible.

Today, the FDA approved vonoprazan dual and triple therapies, developed by Phathom Pharmaceuticals to treat adults with H. pylori infection.

Improving stool sample collecting and testing reduced C difficile underdiagnosis.

Researchers sought to assess antibiotic prescriptions associated with COVID-19 outpatient visits in Medicare beneficiary patients over the course of a year during the pandemic.

Historically low incidence of dengue in southeast Asia and Latin America linked to COVID-19 restrictions suggests potential future interventions.

Dr. Simon Portsmouth of Shionogi discusses the trial results of their once-daily oral COVID-19 antiviral, S-217622, as well as the significance of the therapy as vaccine efficacy wanes in the age of Omicron.

About 65% of patients with metronidazole-resistant recurrent C difficile infection benefitted from taking rifaximin.

Utilization of ambulatory care services declined during the COVID-19 pandemic, especially among socioeconomically disadvantaged Americans.

These behind-the-scenes, essential personnel remain a significant part of health care and is a field with growth opportunities, but remain a field in need of public awareness to enable its stability.

New models suggest that climate change will force animal populations to migrate, creating conditions for new viruses to emerge and jump to humans.

A Colorado person tested positive for avian influenza. The patient worked closely with poultry, their only symptom was fatigue, and they have since recovered after a few days.

Cancer increased risk of COVID-19 among the vaccinated, with subsequent "significant and substantial" hospitalizations and mortality.

Antibiotic overuse is a longstanding problem in the medical community. A new study highlights the benefits of accurate point-of-care testing to differentiate between bacteria and viruses.

Today, the FDA approved oteseconazole to treat recurrent vulvovaginal candidiasis (RVVC). Marketed under the name Vivjoa, the drug is the first FDA approval for manufacturer Mycovia Pharmaceuticals.

Ensovibep, the COVID-19 antiviral treatment developed by Novartis and Molecular Partners, is facing delays in its quest for emergency authorization after the FDA indicated more study data is required.

If authorized, this would be the first vaccine applicable to the youngest pediatric group.

A recent study examined whether immune response to the Pfizer-BioNTech COVID-19 vaccine differed by age and gender.

These paramount medical personnel behind the scenes are facing staffing challenges that could be bordering on a national crisis in public health.

Lasting 505 days, investigators documented the longest known COVID-19 infection. The research, presented at ECCMID, also found one of the first cases of occult COVID-19, in which a patient who tests negative is later found to have ongoing COVID-19.

The filing included data from their phase 2/3 trial in this pediatric age group.

A shorter dosing period and no extra risk of suffering acute myocardial infarction means the newer 2-dose hepatitis B vaccine is an attractive option for protection.

An ECCMID study found COVID-19 primary infections were more severe than reinfections, and vaccination further reduced symptoms.